81.26
+2.98%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Disc Medicine
From its filings with the US Securities and Exchange Commission
Disc Medicine is based in Watertown, Massachusetts. Its shares trade on Nasdaq under the ticker IRON. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported a net loss of $212.2m. At that date it held total assets of $806.9m and shareholders' equity of $739.8m.
We are a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. We have assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Our current pipeline includes bitopertin for the treatment of erythropoietic porphyrias, or EPs, including erythropoietic protoporphyria, or EPP, and X-linked protoporphyria, or XLP; DISC-0974 for the treatment of anemia of myelofibrosis, or MF, and anemia of inflammatory bowel disease, or IBD; and DISC-3405 for the treatment of polycythemia vera, or PV, sickle cell disease, or SCD, and other hematologic disorders. In addition, our preclinical programs include DISC-0998 for the treatment of anemia associated with inflammatory diseases. Our approach to product candidate development leverages well-understood molecular mechanisms that have been validated in humans. We believe that each of our product candidates, if approved, has the potential to improve the lives of patients suffering from hematologic diseases.
Quoted from its 10-K, filed 26 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 12 Aug 2020
- Employees
- 155
- Website
- discmedicine.com ↗
- Head office
- 321 ARSENAL STREET, SUITE 101, WATERTOWN, MA, 02472
- Classification
- Pharmaceutical Preparations
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Dr. Donald NicholsonExecutive Chairman of the Board, since 2022$446,675
- Dr. John QuiselPresident, Chief Executive Officer, Director, since 2022$9.1m
- Ms. Jean FranchiChief Financial Officer$5.3m
- Mr. Jonathan YuChief Operating Officer$2.9m
- Dr. Rahul KharaChief Legal Officer
- Dr. William SavageChief Medical Officer$3.1m
- Ms. Pamela StephensonChief Commercial Officer$5.2m
- Mr. Nadim AhmedDirector
- Dr. Georges GemayelDirector, since 2021$322,675
- Mr. Kevin BittermanIndependent Director$335,675
- Mr. Mark ChinIndependent Director$330,175
- Dr. Liam RatcliffeIndependent Director$334,175
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 32
- Environment
- 30
- Social
- 63
- Governance
- 3
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Disc Medicine Inc focuses on hematologic diseases with a strong pipeline including bitopertin for erythropoietic porphyrias.
- The company targets red blood cell biology pathways like heme biosynthesis and iron homeostasis for innovative treatments.
- Disc Medicine has a portfolio of therapeutic candidates addressing anemia in myelofibrosis and chronic kidney disease.
Weaknesses
- The company employs only 46 full-time employees as of the latest report.
- Disc Medicine's IPO was in 2020 with limited financial history for investors.
- The firm's pipeline includes only a few therapeutic candidates at early stages.
Opportunities
- The growing market for hematologic disease treatments offers significant expansion potential.
- Disc Medicine can leverage its focus on heme biosynthesis to develop new therapies.
- Collaborations with healthcare providers could enhance the commercialization of DISC-0974.
Threats
- Competition from established biopharmaceutical companies in the hematologic disease sector.
- Regulatory challenges may delay the approval of bitopertin and DISC-0974.
- Economic downturns could impact funding for early-stage biotech research.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.